Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide + interferon + interleukin-2 for refractory/relapsed or elderly acute myeloid leukemia
ChiCTR-ONC-14004688Phase 4Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2014
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of thalidomide and aldesleukin in acute myeloid leukemia (AML), sponsored by Henan Cancer Hospital. Primary endpoints: overall response rate, complete remission and 1 more. Started Jun 2014; status: recruiting.
02
Drugs
thalidomidealdesleukin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-ONC-14004688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-14004688.